Remigromig Meets Endpoint, But Raises Safety Concerns

Merck has announced that its investigational tri-specific antibody, remigromig, met its primary endpoint in a Phase 2b/3 clinical trial for adults with diabetic macular edema.

The trial, known as the BRUNELLO study, compared remigromig to ranibizumab and found that both doses of remigromig (0.5 mg and 0.8 mg) showed non-inferiority in measuring best-corrected visual acuity change at week 52.

However, the trial results also indicated higher rates of adverse events among patients receiving remigromig, including proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations.